Crinetics Pharma Earnings Call: Launch, Pipeline, Runway

Crinetics Pharma ((CRNX)) has held its Q4 earnings call. Read on for the main highlights of the call.

Crinetics Pharma’s latest earnings call struck an upbeat tone, balancing a cautiously modest launch with clear clinical and financial strengths. Executives highlighted strong early uptake for new acromegaly drug PALSONIFY, compelling late-stage data, and a cash pile expected to last into 2030, while acknowledging that revenues still lag a growing cost base.

PALSONIFY Launch Shows Early Momentum but Small Revenue Base

PALSONIFY, the oral paltusotine tablet for acromegaly, generated $5.4 million in U.S. net product revenue in Q4 2025 and lifted total quarterly revenue to $6.2 million including licensing. More than 200 enrollment forms and over 125 unique prescribers, spanning community practices and pituitary centers, signal broad early engagement despite the nascent stage of the launch.

Payers Begin to Line Up Behind PALSONIFY

Management pointed to early payer momentum, with several top plans adding PALSONIFY to formularies under label-consistent prior authorization terms and no step edits. This clean access profile reduces the need for patients to fail older therapies first, potentially smoothing adoption over time as coverage scales across commercial and government payers.

Balance Sheet Strength Offers a Long Runway

Crinetics ended 2025 with more than $1.0 billion in cash, cash equivalents, and investments, then added roughly $380 million via a January 2026 equity offering. With about $1.4 billion on hand, the company believes it can fund PALSONIFY commercialization and multiple pivotal trials into 2030, easing near-term financing risk for equity investors.

Atumelnant Delivers Striking Biomarker Responses

Atumelnant, an ACTH receptor antagonist for ACTH-dependent Cushing’s syndrome, produced rapid and large biomarker changes in NIH Phase Ib/IIa data, including urine-free cortisol improvements within days. All treated patients reached serum cortisol below 5 micrograms per deciliter, supporting the drug’s potential to normalize cortisol in a hard-to-treat endocrine disorder.

Seamless Global Phase II/III EQUILIBRIUM Program Underway

The company has launched the global EQUILIBRIUM ADCS Phase II/III trial, designed as an operationally seamless program to accelerate development. Phase II will test doses between 20 and 80 milligrams per day, while Phase III is powered to show normalization of 24-hour urine-free cortisol, and an open-label extension aims to gather longer-term safety and durability data.

CRN09682 Opens New Front in Oncology Pipeline

Crinetics advanced CRN09682, the first asset from its non-peptide drug conjugate platform, into a Phase I/II basket trial called BRAVESST. The study targets SST2-expressing tumors, including neuroendocrine tumors and meningiomas, with PET-based selection criteria and preclinical signals that extend even into models of small cell lung cancer.

European Regulatory Win Supports Global Strategy

In Europe, PALSONIFY secured a positive opinion from the CHMP for treating acromegaly, marking a pivotal regulatory milestone. While commercial details were not deeply discussed, this step supports Crinetics’ ambition to build PALSONIFY into a global growth driver, broadening the addressable patient base beyond the U.S. market.

Cash Use in 2025 Came in Better Than Expected

The company used $326.2 million of net cash in 2025, improving versus prior guidance of $340 million to $370 million. Management attributed the favorable variance to working capital timing and higher proceeds from employee stock option exercises, framing it as evidence of disciplined execution against its spending plans.

Revenue Still Trails Heavy R&D and SG&A Spend

Despite the promising launch, full-year 2025 revenue totaled just $7.7 million against a hefty operating cost structure, with Q4 R&D at $85.1 million and SG&A at $53.7 million. The mismatch underscores that PALSONIFY remains in early ramp-up and that the value proposition for shareholders hinges heavily on successful trial outcomes and future market penetration.

2026 Operating Expenses Set to Climb Further

For 2026, Crinetics projected GAAP operating expenses between $600 million and $650 million and non-GAAP expenses of $480 million to $520 million. The increase reflects a full year of PALSONIFY commercialization and stepped-up clinical spending, signaling continued sizable cash burn even with the current balance sheet buffer.

Reimbursement and Access Still a Work in Progress

At launch, roughly half of PALSONIFY patients were covered through commercial, Medicare, or Medicaid insurance, while the other half relied on the company’s Quickstart bridging program. This split highlights that payer processes are still ramping, and a key watchpoint will be how quickly bridge patients transition into fully reimbursed commercial prescriptions.

Limited Visibility on Near-Term Launch Trajectory

Management declined to provide specific prescription metrics for early 2026, cautioning that the launch trajectory could be “lumpy” from quarter to quarter. That stance leaves investors with limited short-term visibility on revenue trends and places more emphasis on qualitative indicators and payer access updates to gauge momentum.

COGS Low Today but Manufacturing Investment Building

Cost of product revenue in Q4 was modest at $1.1 million, with most commercial inventory still carried at effectively zero cost and less than $100,000 tied to that inventory in the quarter. However, the company is already incurring about $826,000 in manufacturing readiness and supplier qualification expenses, signaling that cost of goods will likely rise as volumes scale.

Early Launch Metrics Encouraging but Inconclusive

Management framed the more than 200 enrollment forms and 125 prescribers as promising, yet emphasized that PALSONIFY remains in the early innings of its commercial life. Key unknowns include the time it takes to convert enrollments into reimbursed therapy and what long-term market share the drug can capture against established therapies.

Guidance Underscores High Spend and Deep Cash Reserves

Crinetics’ 2026 guidance pairs elevated operating expense expectations with confidence in its multi-year funding runway. With Q4 2025 revenue at $6.2 million, continued distribution of zero-cost inventory for several quarters, and roughly 105 million common shares outstanding, management maintained that its approximately $1.4 billion cash position is sufficient to support operations and major clinical milestones into 2030.

Crinetics’ earnings call painted a picture of a company in transition from pure development to an integrated commercial-stage biotech with multiple shots on goal. While near-term revenues remain modest and expenses are rising, investors heard a story anchored in a strong launch foundation, high-impact clinical assets, and a balance sheet designed to carry the strategy through the end of the decade.